Delving into the Latest Updates on Pfizer Europe MA EEIG with Synapse

Overview

Tags

Other Diseases

Skin and Musculoskeletal Diseases

Neoplasms

Small molecule drug

Biosimilar

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	24
Neoplasms	24
Nervous System Diseases	20
Infectious Diseases	20
Immune System Diseases	19
Endocrinology and Metabolic Disease	16

Top 5 Drug Type	Count

Small molecule drug	31
Biosimilar	8
Monoclonal antibody	6
Prophylactic vaccine	6
Colony-stimulating factors	3

Top 5 Target	Count

TTR(Transthyretin)	2
TNF-α(Tumor necrosis factor α)	2
HER2(Receptor tyrosine-protein kinase erbB-2)	2
GHR(Growth hormone receptor)	2
CSF-3R(Colony stimulating factor 3 receptor)	2

The primary objective of this study was to further characterize the safety profile of sildenafil in the treatment of Chinese adult PAH patients in a real-world setting. The secondary objective was to describe the effectiveness of sildenafil in the treatment of Chinese adult PAH patients in a real-world setting.

Start Date23 Dec 2021

Sponsor / Collaborator

Pfizer Investment Co. Ltd.

[+2]

100 Clinical Results associated with Pfizer Europe MA EEIG

Login to view more data

0 Patents (Medical) associated with Pfizer Europe MA EEIG

Login to view more data

100 Deals associated with Pfizer Europe MA EEIG

Login to view more data

100 Translational Medicine associated with Pfizer Europe MA EEIG

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 31 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

NDA/BLA

3

55

Approved

Other

5

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Tucatinib ( HER2 )	HER2 Positive Breast Cancer More	Approved
Temsirolimus ( FKBP12 x mTOR )	Mantle-Cell Lymphoma More	Approved
20-valent Pneumococcal Conjugate Vaccine(Pfizer)	Invasive streptococcal disease More	Approved
Nirmatrelvir/Ritonavir ( CYP3A x SARS-CoV-2 3CLpro )	COVID-19 More	Approved
Meningococcal group B vaccine(Pfizer Inc.)	Meningococcal Infections More	Approved